Why Indaptus Therapeutics, Inc.’s (INDP) Stock Is Up 5.13%
As of Tuesday, October 20, Indaptus Therapeutics, Inc.’s INDP share price has surged by 5.13%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Commentary & Analysis
Why Indaptus Therapeutics, Inc.’s (INDP) Stock Is Down 5.26%
As of Friday, October 16, Indaptus Therapeutics, Inc.’s INDP share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Indaptus Therapeutics, Inc.’s (INDP) Stock Is Up 9.95%
As of Thursday, October 15, Indaptus Therapeutics, Inc.’s INDP share price has surged by 9.95%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Indaptus Therapeutics, Inc.’s (INDP) Stock Is Up 19.00%
As of Thursday, October 15, Indaptus Therapeutics, Inc.’s INDP share price has surged by 19.00%, which has investors questioning if this is right time to sell.Tudor Pop
Why Indaptus Therapeutics, Inc.’s (INDP) Stock Is Down 9.62%
As of Wednesday, October 14, Indaptus Therapeutics, Inc.’s INDP share price has dipped by 9.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | INDP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $394.4 | $228.4 | 35% |
|
| Shares Out (Mil) | 116.1 | 53.9 | 65% |
|
| Institutional Ownership | 0.4% | 92.9% | 1% |
|
| Float (Mil) | 23.7 | 41.7 | 31% |
|
| Beta | 1.18 | 0.95 | 69% |
|
| Avg Daily Volume (000s) | 472 | 582 | 57% |
|
| Price Change (52-week) |
(20.0%) | 47.6% | 36% |
|
| Growth | INDP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (42.0%) | (10.1%) | 9% |
|
| EPS (5yr) | 16.0% | 15.8% | 60 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.9% | (15.7%) | 75% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | INDP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($15) | ($44) | 26% |
|
| EPS (TTM) | ($0.471) | ($1.500) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($33) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $172 | $177 | 25% |
|
| Valuation | INDP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 32.89 | 2.19 | 98% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | INDP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (163.8%) | (47.1%) | 3% |
|
| ROE | (318.0%) | (54.1%) | 3% |
|
| Liabilities to Assets | 5.1% | 29.1% | 2% |
|
| F-Score | 3 | 2 | 18% |
|
Indaptus Therapeutics, Inc. did not pass any screens on 10/20/2026.
